Latest filings (excl ownership)
15-12G
Securities registration termination
16 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
EFFECT
Notice of effectiveness
14 Mar 23
25-NSE
Exchange delisting
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
POS AM
Prospectus update (post-effective amendment)
6 Mar 23
8-K
Completion of Acquisition or Disposition of Assets
6 Mar 23
SC TO-T/A
Third party tender offer statement (amended)
6 Mar 23
SC 14D9/A
Tender offer solicitation (amended)
6 Mar 23
SC TO-T/A
Third party tender offer statement (amended)
24 Feb 23
SC 14D9/A
Tender offer solicitation (amended)
24 Feb 23
SC 14D9
Tender offer solicitation
2 Feb 23
SC TO-T
Third party tender offer statement
2 Feb 23
SC TO-C
Information about tender offer
1 Feb 23
SC TO-C
Information about tender offer
31 Jan 23
SC14D9C
Written communication relating to third party tender offer
19 Jan 23
SC TO-C
Information about tender offer
19 Jan 23
SC14D9C
Written communication relating to third party tender offer
19 Jan 23
8-K
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
19 Jan 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Other Events
22 Aug 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
4 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 22
8-K
Concert Pharmaceuticals Announces Pricing of Public Offering
3 Jun 22
424B5
Prospectus supplement for primary offering
3 Jun 22
Latest ownership filings
4
Heek Christi van
6 Mar 23
4
Roger D Tung
6 Mar 23
4
Nancy Stuart
6 Mar 23
4
Jeffrey A Munsie
6 Mar 23
4
WILFRED E JAEGER
6 Mar 23
4
PETER BARTON HUTT
6 Mar 23
4
Jesper Hoeiland
6 Mar 23
4
James V Cassella
6 Mar 23
4
Marc A. Becker
6 Mar 23
4
Thomas G Auchincloss
6 Mar 23
4
RICHARD ALDRICH
6 Mar 23
4
Nancy Stuart
16 Feb 23
4
Jeffrey A Munsie
16 Feb 23
4
James V Cassella
16 Feb 23
4
Marc A. Becker
16 Feb 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G
Kynam Capital Management, LP
13 Feb 23
SC 13G
Kynam Capital Management, LP
10 Feb 23
4
Nancy Stuart
31 Jan 23
4
Jeffrey A Munsie
31 Jan 23
4
James V Cassella
31 Jan 23
4
Marc A. Becker
31 Jan 23
4
Roger D Tung
9 Jan 23
4
Nancy Stuart
9 Jan 23
4
Jeffrey A Munsie
9 Jan 23
4
James V Cassella
9 Jan 23
4
Marc A. Becker
9 Jan 23
4
PETER BARTON HUTT
18 Oct 22
4
Heek Christi van
13 Jun 22
4
WILFRED E JAEGER
13 Jun 22
4
PETER BARTON HUTT
13 Jun 22
4
Jesper Hoeiland
13 Jun 22
4
Thomas G Auchincloss
13 Jun 22
4
RICHARD ALDRICH
13 Jun 22
4
Heek Christi van
6 Jun 22
4
Thomas G Auchincloss
6 Jun 22
4
RICHARD ALDRICH
6 Jun 22
4
Roger D Tung
16 Feb 22